💰 North Carolina approved a grant up to $4.9 million to support this expansion.
📈 The new facility, costing $1 billion, will create about 370 jobs.
🌍 Amgen aims to enhance global manufacturing and meet rising demand for innovative therapies.
Introduction:
The recent announcement by Amgen to increase its biomanufacturing investment in Holly Springs, North Carolina, to $1.5 billion highlights the growing importance of biotechnology in the region and the broader commitment of the company to enhance its manufacturing capabilities in response to rising global demand for innovative therapies.
- Amgen is establishing a second drug substance manufacturing plant in Holly Springs, NC, with a projected cost of $1 billion, contributing to a total investment of $1.5 billion in the area.
- The new plant follows the ongoing construction of Amgen’s first facility in the region, a $550 million project expected to begin operations in 2025 and create approximately 355 jobs.
- The anticipated economic impact of the Amgen expansion includes a projected growth of North Carolina’s economy by $3.59 billion, bolstered by a Job Development Investment Grant valued at nearly $5 million from the state.
- The combined employment from both facilities is estimated to be 370 jobs, reflecting Amgen’s commitment to bolstering its workforce while serving global patient needs.
- Amgen’s expansion aligns with a broader trend of biopharmaceutical companies investing in North Carolina, a leading biotechnology hub, enabling better support for increasing market demands.
Conclusion:
Amgen’s enhanced investment in North Carolina signifies the strategic importance of the region for biomanufacturing and underscores the company’s dedication to meeting global healthcare demands. The expansion not only promises substantial economic growth for the area but also enhances the competitive landscape of North Carolina as a biotechnology center, facilitating collaboration and innovation within the industry.
